The Four Key Trends In Pharmaceutical Alliances
As the worst threats of managed care receded, the industry saw an explosion in the number of available, innovative late-stage drugs, both from biotechs and from mid-sized companies unable to sell them on their own. Genomics and combinatorial chemistry burst onto the R&D scene, generating a huge wealth of targets and compounds. The result has been a sudden return to the roots of the drug industry: finding and selling innovative branded products.
You may also be interested in...
Moderna's vaccine has shown encouraging early results in younger adults, but over-55s and over-70s cohorts represent a bigger safety and efficacy hurdle.
Will FDA-cleared prescription digital therapeutics be able to follow wellness, chronic disease and sleep disorder apps onto the formularies of major payers? For digital therapeutics companies investing in randomized controlled clinical trials, GMP manufacturing and FDA submissions for products, the current absence of public health insurance coverage is frustrating.
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.